G3BP2 and neoplasm: In an vivo study, inhibiting G3BP2 activity by knocking down MG53 significantly reduced tumor volume and weight in mouse lung cancer model [41], which suggests that targeting G3BP2 had a significant anticancer effect in NSCLC.